Startup Equity: Founders’ 2026 VC Term Sheet Risks

The fluorescent hum of the WeWork office in Midtown Atlanta felt particularly oppressive to Sarah Chen that Tuesday morning. Her startup, Aura Health, an AI-driven platform for personalized mental wellness, was on the cusp of something big. They’d just closed their seed round, and a Series A term sheet from Atlas Ventures sat on her desk, a thick stack of legalese that felt more like a brick wall than a bridge to their next stage of growth. Her co-founder, Ben, a brilliant engineer but notoriously impatient with paperwork, had already skimmed it and declared it “standard.” Sarah, however, felt a gnawing unease. She knew a VC term sheet wasn’t just a formality; it was the foundational contract that would dictate Aura Health’s future, its control, and ultimately, its founders’ fortunes. How much did she really understand about the fine print of their startup equity and the long-term implications of these seemingly innocuous investment terms?

I’ve seen this scenario play out countless times in my career advising early-stage companies. Founders, brimming with passion for their product, often treat the term sheet as a necessary evil, something to get through quickly so they can return to building. This is a monumental mistake. The term sheet is where the true power dynamics are set, where future conflicts are either averted or baked in. It’s not just about the valuation; it’s about control, exit scenarios, and how much of your company you truly own when it matters most.

Sarah’s initial concern wasn’t about the valuation itself – Atlas Ventures had offered a respectable $20 million pre-money. Her eyes kept drifting to a clause titled “Liquidation Preference.” Ben had shrugged it off, saying, “It’s 1x, that’s normal.” But what did “1x non-participating” versus “1x participating” actually mean? I remember a particularly painful situation with a client, a robotics startup called Synapse Robotics, back in 2022. They had accepted a 1.5x participating liquidation preference without fully grasping its implications. Two years later, when the company was acquired for a modest $30 million – a decent outcome for investors, but not a home run – the founders, despite owning a significant chunk of common stock, walked away with far less than they anticipated. The investors, with their participating preference, not only got their initial investment back 1.5 times over, but they also shared in the remaining proceeds as if they were common shareholders. It was a brutal lesson in financial literacy, and one I swore my future clients wouldn’t repeat.

For Aura Health, the Atlas Ventures term sheet specified a 1x non-participating liquidation preference. This is generally considered founder-friendly. It means that in an acquisition or liquidation event, Atlas Ventures gets their initial investment back first (1x their money), and then the remaining proceeds are distributed among all shareholders, including Atlas, based on their equity percentages. They don’t “double dip” by getting their money back and then participating in the remaining pool as well. This was a win for Sarah, even if she didn’t fully appreciate it at first glance. I advised her to ensure this remained non-participating throughout negotiations. A participating preference, especially anything above 1x, can severely dilute founder payouts in less-than-stellar exits.

Next on Sarah’s list of worries was the Vesting Schedule. The term sheet proposed a standard 4-year vesting schedule with a 1-year cliff. This means that if she or Ben left the company before one year, they’d forfeit all their unvested founder shares. After the first year, their shares would vest monthly over the remaining three years. “What if I get hit by a bus?” Sarah joked darkly to me during our call, but her underlying anxiety was real. Founders pour their lives into these ventures. Losing equity due to unforeseen circumstances or even a disagreement with investors can be devastating. I always push for what’s fair. While a 4-year vest with a 1-year cliff is standard, founders should also consider negotiating for accelerated vesting in specific scenarios, such as a change of control (acquisition) or if they are terminated without cause. This protects them from being unfairly stripped of their hard-earned equity.

Aura Health’s board structure was another point of contention. Atlas Ventures proposed a five-person board: two investor seats, two founder seats, and one independent director mutually agreed upon. This seemed balanced on the surface, but it meant that in any disagreement, the independent director held the swing vote. And who appoints that independent director? Often, it’s heavily influenced by the investors. My advice to Sarah was clear: push for a founder majority or at least a situation where founders and investors have equal representation, with the independent director truly neutral. For a Series A, a 2-2-1 split isn’t uncommon, but founders should fight for their ability to appoint that independent director, or at least have a strong veto over candidates. Control, especially in the early stages, is paramount. You need the ability to execute your vision without constant second-guessing from investors who might have different timelines or risk appetites.

One clause that often trips up even seasoned founders is Protective Provisions. These aren’t just minor details; they are powerful veto rights granted to investors. Atlas Ventures’ term sheet included provisions requiring their consent for actions like selling the company, incurring significant debt, amending the company’s certificate of incorporation, or even approving the annual budget. Sarah initially thought, “Well, these are big decisions, of course they should have a say.” But the devil is in the details. What constitutes “significant” debt? What if a minor amendment to the incorporation documents is needed for a routine regulatory filing? I once advised a fintech startup, CashFlow, based out of the Atlanta Tech Village, where the protective provisions were so broad that the founders needed investor approval to hire any employee above a certain salary threshold. It became a bureaucratic nightmare, slowing down their growth dramatically. We painstakingly negotiated to narrow the scope of these provisions, ensuring they applied only to truly material events, not day-to-day operations. For Aura Health, I recommended Sarah push to raise the thresholds for debt requiring approval and to specify that only major strategic decisions, not operational ones, would require investor consent.

Finally, we addressed Pro-Rata Rights. This clause gives investors the right to participate in future funding rounds to maintain their ownership percentage. While this sounds fair, it can also mean that a large investor can take up a significant portion of a future round, potentially crowding out new, strategic investors who might bring more than just capital to the table. “I want new investors who bring connections, not just cash,” Sarah emphasized. I explained that while you can’t typically remove pro-rata rights, you can negotiate their scope. For instance, sometimes founders can negotiate a carve-out for strategic investors or cap the amount an existing investor can participate in a future round. It’s a delicate balance; you want existing investors to feel valued, but you also need flexibility to bring in the best partners for your next stage of growth.

After two weeks of intense back-and-forth, often involving late-night calls and frantic email exchanges, Sarah and Ben finalized their Series A term sheet with Atlas Ventures. They successfully negotiated a slightly lower valuation (a small concession for greater control), maintained the 1x non-participating liquidation preference, secured accelerated vesting for specific termination events, narrowed the scope of protective provisions, and ensured that the independent board member would be mutually agreed upon with a strong founder veto. Sarah felt a profound sense of relief, but also empowerment. She hadn’t just signed a document; she had actively shaped her company’s future. The process had been grueling, but understanding these complex investment terms was the difference between building her dream and potentially losing control of it.

My biggest takeaway for any founder is this: never treat your term sheet as a secondary concern. It’s the blueprint for your journey, and every clause has a ripple effect. Invest the time, engage experienced legal counsel, and understand every single line. Your future self, and your bank account, will thank you. For more insights on securing startup funding, especially for those navigating early stages, remember that every negotiation shapes your trajectory. And while navigating these complex financial waters, remember that a strong business strategy will always be your most valuable asset.